Amoeba SA · EURONEXT:ALMIB
Amoeba SA — Non-Deal Roadshow (October 2022)
28 slides from Amoeba SA's roadshow presentation, October 2022

Slide 1: Roadshow Presentation 2022
tena) hate a avioéba ns ROADSHOW PRESENTATION 2022 |

Slide 2: Disclaimer
DISCLAIMER When receiving this presentation or participating in this meeting, you acknowledge having taken note of the following restrictions. The present document and the information contained in the presentation are strictly confidential. This document cannot be copied, reproduced, distributed, pu

Slide 3: Amoeba's Market Valuation
AMOEBA’S MARKET VALUATION CAP 2022 Submission of Market Cap R&D stage an AMM dossier Commercialization 200 M€ Agrauxine * 100% / € 45M Biotalys * 0% / Outsourcing 100 M € Antofénol Amoéba * 13% / € 53 M * 13% / € 17 M 50 M € Maturity * Functional plant / investment

Slide 4: Amoeba's TAM Positioning
TAM 12 MDSPOSITIONING AMOEBA’S EUROS Rice Strawberry Env. € 1000 M In the testing process Vines Vegetables Potato Arboricultures € 800M € 600M € 250M Banana and others (powdery and mildew ) Env. € 500 M Env. € 100 M Wheat Soybeans € 2 400M € 2 100M Global Market potential : € 7 750 Mds

Slide 5: Biocide, a Valuable Asset of Amoeba
BIOCIDE, A VALUABLE ASSET OF AMOEBA The first biological biocide for industrial water treatment • A patented innovation in a sector that has been stagnant for 50 years • Favorable pre-decision in the USA for use in closed cooling systems (definitive at the end of 2022) $ 10 M Of construction costs f

Slide 6: 2024 Forecast
2024 FORECAST To guarantee the emergence of a future French world leader in biocontrol Contribute to the creation of a biocontrol industrial network in France Thanks to our solid pillars Scientific maturity • 10 years of R&D • 9 scientific publications Regulatory maturity • Europe: Recommendation fo

Slide 7: Towards a New Request to the Market
TOWARDS A NEW REQUEST TO THE MARKET « Since the creation of Amoéba, our funding has allowed us to reach a level of maturity on our 3 pillars: scientific, industrial and regulatory. Our objectives have been reached, notably by the completion of numerous field trials, the positive recommendation of Au

Slide 8: Amoeba Presentation
1 AMOEBA PRESENTATION co amoeba

Slide 9: About Amoeba
ABOUT AMOEBA Amoéba is a Lyon-based biotech company specialized in the treatment of microbiological risk for natural resources. 1 microorganism, 2 applications Live amoeba BIOCIDE Dedicated to industrial water treatment Lysate of amoeba BIOCONTROL PRODUCT Dedicated to crop protection

Slide 10: Our Vision and Mission
OUR VISION AND MISSION Ensuring a sustainable Develop a scientific and future by offering biological industrial expertise to alternatives that respect contribute to expand the human health and the offer of eco-friendly environment products Demonstrate our relevance Leading the way for other and posi

Slide 11: Amoeba Key Figures
AMOEBA KEY FIGURES 25 Millions of euros invested in R&D since 2010 26 Employees in France 1 Industrial center dedicated to our production

Slide 12: Board of Directors
COMITE DEDIRECTORS BOARD OF DIRECTION Fabrice Plasson Valérie Filiatre Bernard Ambolet CEO Administrator & Administrator Expert in life science and Chief Financial Officer Expert in agriculture and biotechnologies Expert in business administration Biocontrol and finance Pierre Morgon Sylvie Guinard

Slide 13: Comité de Direction
COMITE DE DIRECTION Fabrice Plasson Valérie Filiatre Jean-Luc Souche CEO Administrator & Business Developer Biocontrol Expert in life science and Chief Financial Officer Specialist in plant protection biotechnologies Expert in business administration and finance Sandrine Troussieux Jean-Baptiste Ebe

Slide 14: Financial Informations
2 - FINANCIAL INFORMATIONS ha al

Slide 15: Financing and Shareholding
FINANCING AND SHAREHOLDING Distribution of € 13.2 M Raised during the IPO in July 2015 shareholding € 14.7 M Raised in 2016 by private placement 5% Financing agreement with the European €5M Investment Bank (EIB) in 2017 € 15,8 M OCAPI with Nice & Green between 2018 and 2021 95% €6M Other funds raise

Slide 16: Financial Situation
FINANCIAL SITUATION SITUATION FINANCIERE BURN RATE EIB DEBT Refunded in June 2022 2020 2021 2020 2021 € 410 K € 370 K € 7,9 M € 6,1 M EQUITY CASHFLOW 2020 2021 2020 2021 € 2,0 M € 0,2 M €5M € 7,3 M

Slide 17: Biocontrol
' BIOCONTROL he ' py f

Slide 18: État de l'art – Biocontrol Context
ETAT DE L’ART – BIOCONTROLE CONTEXT EUROPEAN OBJECTIVE Limited biocontrol High solutions To find "green" alternative but environmental Ancient pesticides equally effective solutions. impact increasingly banned 78% reduction of (EU), including copper insects between submitted for re- 1989 and 2013 ev

Slide 19: Our Solution
OUR SOLUTION A 100% natural biofungicide Effectiveness in 50-80% fields In-field trials by 300 Amoéba since 2019 180 In-field trials by partners since 2019

Slide 20: Value Proposition
VALUE PROPOSITION Facilitating the transition from conventional to organic agriculture Conventional Organic Substitutes market market Thanks to our solution : • A unique dual mode of action (elicitor and fungicide) • A wide spectrum of activity (vineyards, vegetables, potatoes, cereals...) • A good

Slide 21: Key Factors of Success
KEY FACTORS OF SUCCESS An innovative and unique product An active substance recommended from a class of microorganisms never for approval by the Rapporteur used before in agriculture: amoebas Member State (Austria) A product with no hazard class A product with no residue limit and a low risk profile

Slide 22: Industrialization
4 INDUSTRIALIZATION

Slide 23: Industrialization
INDUSTRIALIZATION Chassieu Industrial R&D Center 2 x 500 L Production capacity of bioreactors 500 KG of active substance produced per year

Slide 24: Production Site Expansion Project
PRODUCTION SITE EXPANSION PROJECT Creation of a new duplicable factory Biocontrol production line 30 T of additional active substance Capacity 20x higher than Chassieu € 17 M of investments A certified site "Label Parc+". • Preservation and valuation of the environment • 80% of roofs covered with ph

Slide 25: Optimization of Industrial Performance
OPTIMIZATION OF INDUSTRIAL PERFORMANCE 2022 2023 2024 APS APD PC Instruction Construction site Qualif. Go Live INDUSTRIAL PROJECT NOE (existing test line) Pilot line (Chassieu) USIBIAM (Vaucluse) Bioreactor : 1 x 3000 L Bioreactors : 4 x 5000 L Bioreactors : 2 x 500 L Implementation of a pilot A.I.

Slide 26: Amoeba's TAM Strategy 2024-2026
AMOEBA’S TAM 12 MDSSTRATEGY EUROS 2024-2026 A volume and profitability strategy 40 tons of AS/year = 100 000 hectares treated Vines Lettuce Tomato Aromatic herbs (2 771 000 hectares) (500 000 hectares) (280 000 hectares) (30 000 hectares) Price/ Price/ Price/ Price/ ha ha ha ha 50 € 80 € 80 € 200 €

Slide 27: Amoeba's Project Financing
AMOEBA’S PROJECT FINANCING FUNDING € 5,9 M € 32 M Maximum funding « France 2030 » (35%) required for the realization of the project € 3,2 M Current bond issue € 17 M €5M Dedicated to the factory construction Bank loan € 15 M € 18 M Dedicated to operating expenses over Capital increase 2023 - 2024

Slide 28: Social Media, Website, Contact
Social Media Website Contact @AmoebaNature amoeba-nature.com contact@amoeba-nature.com ROADSHOW PRESENTATION 2022
Source: Internet Archive copy of amoeba-nature.com
More decks from Amoeba SA
Investor Presentation (October 2026)12 slides · October 2026
Investor Presentation (May 2026)28 slides · May 2026
Investor Presentation (December 2025)23 slides · December 2025
Investor Presentation (December 2025)23 slides · December 2025
Shareholder Meeting (June 2025)18 slides · Jun 26, 2025
Shareholder Meeting (June 2025)20 slides · Jun 26, 2025